Latest News - Stryker Corporation
Top Corporates Hub
Stryker Corporation
Assessing Stryker (SYK) Valuation After Recent Share Performance And Cash Flow Expectations
14.02.2026 13:09
Why Stryker (SYK) is back on investors’ radar Stryker (SYK) has been drawing fresh investor attention after recent share price moves and updated return figures, prompting a closer look at how its current performance might fit into a broader portfolio. See our latest analysis for Stryker. Recent trading has been steady rather than dramatic, with a 7 day share price return of 2.17% and a year to date share price return of 5.13%. However, the 1 year total shareholder return of a 4.09% decline...
BSX Posts Q4 Earnings: Should You Buy, Sell or Hold the Stock?
13.02.2026 12:57
Boston Scientific tops Q4 estimates, but shares sink on supply woes and EP losses. Can strong growth drivers fuel a 2026 rebound?
Enovis: Valuation Is Too Low, But Needs To Differentiate On Growth
12.02.2026 06:00
Enovis management has guided for up to low-double-digit Recon growth in 2026. Learn more about ENOV stock and why I maintain my buy rating.
Stryker introduces Mako Handheld Robotics with the limited market release of Mako RPS
09.02.2026 15:29
Stryker (NYSE: SYK), a global leader in medical technologies, announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, an intuitive handheld robotic system that combines Stryker's proven robotics and power tool legacies and represents Mako's expansion into a new robotics platform. Mako now includes Mako SmartRobotics™ – Stryker's multi-specialty, robotic-arm assisted platform featuring Mako 4 – and Mako Handheld Robotics with Mako RPS, which is designed to reach a
Hip Replacement Market to Reach US$ 11.4 Billion by 2033 Driven by Aging Population, Rising Osteoarthritis, and Robotic-Assisted Surgery Says Astute Analytica
02.02.2026 15:09
The global hip replacement market is experiencing significant growth, driven by an aging population, rising obesity, and advancements in robotic-assisted surgery. Key trends include increasing demand for minimally invasive procedures, metal-on-polyethylene implants, and specialized orthopedic devices. The industry is dominated by major players such as Stryker, Zimmer Biomet, and DePuy Synthes.Chicago, Feb. 02, 2026 (GLOBE NEWSWIRE) -- According to recent data from Astute Analytica, the global hi
Stryker Q4 Earnings Call Highlights
30.01.2026 07:08
Stryker (NYSE:SYK) executives highlighted double-digit organic growth, record robotic system installations, and another year of margin expansion during the company’s fourth-quarter and full-year 2025 earnings call, while also outlining expectations for continued strength in 2026 despite incremental
Stryker Corp (SYK) Q4 2025 Earnings Call Highlights: Record Revenue and Robust Growth Amid ...
30.01.2026 05:04
Stryker Corp (SYK) reports impressive Q4 and full-year results with double-digit organic sales growth, despite facing tariff headwinds and competitive pressures.
Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript
30.01.2026 00:32
Stryker Corporation (SYK) Q4 2025 Earnings Call January 29, 2026 4:30 PM ESTCompany ParticipantsKevin Lobo - Chairman & CEOJason Beach - Vice President...
SYK's Q4 Results Likely to Reflect Procedure Growth and Capital Demand
28.01.2026 13:24
Stryker's fourth-quarter results are expected to highlight resilient procedure volumes and strong capital demand, supported by product momentum and broad-based strength.
What To Expect From Stryker’s (SYK) Q4 Earnings
28.01.2026 03:13
Medical technology company Stryker (NYSE:SYK) will be reporting results this Thursday after market close. Here’s what to expect.
AVNS & Siemens Healthineers Team Up on Advanced Integrated Pain Care
26.01.2026 15:20
Avanos Medical teams up with an imaging partner to pair RFA with mobile imaging, targeting the shift of complex pain procedures to outpatient care.
Gear Up for Stryker (SYK) Q4 Earnings: Wall Street Estimates for Key Metrics
26.01.2026 14:15
Besides Wall Street's top-and-bottom-line estimates for Stryker (SYK), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
26.01.2026 04:38
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
How The Narrative Around Stryker (SYK) Is Shifting With The Latest Price Target Update
24.01.2026 06:09
The latest update on Stryker centers on a revised price target, reflecting how analysts now frame the stock’s potential based on new information and shifting expectations. This change in price target is less about a single headline event and more about how recent inputs reshape the overall story around the company. Keep reading to see how you can track these kinds of price target moves and stay on top of the evolving narrative going forward. Analyst Price Targets don't always capture the full...
Oppenheimer Questions $14.5B Penumbra Deal Valuation Despite Boston Scientific’s (BSX) Mew Market Dominance
23.01.2026 02:52
Boston Scientific Corporation (NYSE:BSX) is one of the best mid-cap growth stocks to buy right now. On January 16, Oppenheimer lowered its price target on Boston Scientific to $100 from $125 with an Outperform rating. Oppenheimer is cautious on the financial optics of Boston Scientific’s $14.5 billion acquisition of Penumbra. Although the deal creates a […]
Assessing Stryker (SYK) Valuation After Mixed Recent Share Price Performance
16.01.2026 06:08
Stryker stock overview after recent performance shifts Stryker (SYK) has drawn fresh attention after a mixed run, with a small gain over the past month and a slight decline across the past 3 months, prompting investors to reassess the medical technology group. See our latest analysis for Stryker. At a share price of US$362.49, Stryker has delivered a 4.1% year to date share price return, while its 1 year total shareholder return of a 4.2% decline contrasts with a 3 year total shareholder...
NVST vs. SYK: Which Stock Is the Better Value Option?
15.01.2026 16:40
NVST vs. SYK: Which Stock Is the Better Value Option?
Boston Scientific Acquiring Penumbra Was The Logical Next Step
15.01.2026 12:10
Boston Scientificâs $374/share Penumbra deal boosts mechanical thrombectomy exposure and growth. Click here to learn more about BSX stock prospects.
Despite Reassurances On Growth, The Market Hasn't Warmed To Stryker
07.01.2026 08:45
Stryker outlook: 9%+ FYâ26 growth, margin leverage, and attractive valuation vs. med-tech peers. See why I rate SYK stock a Buy.
1 Oversold Stock Primed to Rebound and 2 That Underwhelm
07.01.2026 04:35
Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?